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Objective. Electrochemotherapy (ECT) is an attractive treatment for solid cutaneous tumours with a good
response rate (55–92%). No studies have evaluated ECT performed in vulvar cancer. The aim of our study was
to evaluate the safety, local tumour efﬁcacy and relief of symptoms of ECT treatment in patients affected by
recurrence of squamocellular vulvar cancer (V-SCC) unsuitable for standard treatments.
Methods. We enrolled nine patients with histological diagnosis of recurrence of V-SCC. Intravenous
bleomycin was injected under general sedation after an accurate mapping of all lesions and ECT was
performed. Patients were reviewed after one, three and six months. Response to therapy was evaluated
using RECIST criteria and quality of life (QoL) was evaluated via questionnaires.
Results. The median age was 84 years (range 80–90 years). The main location of recurrences was the
vulva (87.5%). Multiple lesions were present in 25% of cases. No peri-operative complications were observed.
Response to therapy was complete in 62.5% of patients, partial in 12.5%, no change was observed in 12.5% and
progression of disease in 12.5% of patients respectively. Evaluation of symptoms showed a signiﬁcant reduc-
tion of pain, bleeding, odour (p b 0.04) and urinary discomfort (p b 0.04). We observed two relapses at four
and seven months after treatment. After nine months ﬁfty percent of patients were alive.
Conclusions. Our preliminary study showed that ECT is a suitable procedure in elderly patients with
loco-regional vulvar cancer relapses. ECT can be used as palliative therapy and the treatment relieves symptoms
and improves QoL.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Vulvar cancer represents 5% of all female gynaecologic malignancies
and its incidence is 10 times higher in patients over 75 years of age [1].ogy, S. Orsola-Malpighi Hospital,
4392.
.
nc. Open access under CC BY-NC-ND licenseTreatment and management represent a challenge because of its ana-
tomic location, tendency to spread to the lymph nodes and incidence
in the elderly [2].
In the past radical surgery was the primary treatment option in
both early and late stages. Nowadays surgery still has an important
role but neo/adjuvant chemo and radiotherapy are used to decrease
postoperative complications and improve prognosis [3].
Despite this multimodal approach recurrence, especially in advanced
stages, is not rare [4]. Loco-regional recurrence is an important risk factor
for distant metastatic disease, either synchrone or metachrone with a
negative effect on quality of life (QoL) (local pain, vaginal bleeding,.
551A.M. Perrone et al. / Gynecologic Oncology 130 (2013) 550–553burning and odour) [5]. Therapy for this pattern of recurrence is limited
and options are based on the volume and site of the disease. After
multidisciplinary treatment for recurrences surgical resection remains
the preferred therapeutic approach [6]. However when surgery cannot
be performed with a reasonable cosmetic and functional outcome,
other options must be evaluated.
Electrochemotherapy (ECT) is a recent loco-regional therapy that
combines low-dose cytotoxic drugs (bleomcyn and cisplatin), adminis-
tered intravenously or intra-lesionally, and high intensity electric pulses
to induce electroporation to improve drug delivery into tumour cells
[7].
ECT is used in humans for the treatment of cutaneous neoplasms or
the palliation of skin tumour metastases. Since 1995 literature has
reported a 92% response rate in patients treated with ECT for dissemi-
nated cutaneous and subcutaneous melanoma lesions as a palliative
cure [8,9]. In 2006 amulticentre study performed by the European Stan-
dard Operating Procedure for Electrochemotherapy (ESOPE) deﬁned
the parameters for using ECT. ECT can be proposed in cutaneousmetas-
tasis that cannot be excised because of the number and/or site of the
tumour and in a palliative setting the procedure offers a good response
(85%) and improves patient QoL [10].
In literature, no study has previously evaluated whether ECT could
be used for local treatment in cutaneous recurrences of squamous
cellular vulvar cancer (V-SCC).
The aim of this preliminary study was to evaluate the safety, local
efﬁcacy, acceptability and QoL of ECT with bleomycin in reducing the
size of tumours in patients with V-SCC with loco-regional cutaneous
recurrence submitted to multiple previous treatments (chemotherapy,
radiotherapy and surgery) and unsuitable for standard treatments.Materials and methods
In our prospective preliminary studywe recruited ninewomenwith
histological diagnosis of single or multiple loco-regional recurrences of
V-SCC. Patients were unsuitable for standard treatments because of
tumour characteristics (previous multiple surgeries or previous radio-
therapy) and general status and were invited to participate in the
study to undergo palliative therapy with ECT.
Inclusion criteria and technical procedures followed the European
Standard Operating Procedures of ECT Study (ESOPE) [11]. The study
was approved by the local ethical committee and all patients signed
an informed consent form before enrolment.
Before initiating the procedure accurate digital mapping of all le-
sions was performed and the area involved was sketched. All nodules
were measured and the tumour area was calculated [11]. If multiple
nodules were present the area was the sum of the area of each lesion.
A full clinical history, clinical examination, routine blood biochemistry,Table 1
Patients characteristics.
Patients NRa Type Rb Locationc ab before ECT(cm2)d Resp
1 1 S 1r 1.4 PD
2 0 M 2r–2l 2.5–2 CR
3 2 S 3 0.32 CR
4 4 S 5 10 PR
5 3 S 4 2.5 CR
6 1 S 1l 1.5 CR
7 1 S 6r 2.6 SD
8 1 M 3 3 CR
NR = number of recurrence before ECT.
R = Recurrence.
b S = singular recurrence or lesion, M = multiple recurrence or lesion.
c 1 = labium mayus, 2 = labium minus, 3 = posterior commissure, 4 = paraurethral regi
d a = largest diameter of the tumour nodule, b = diameter of the tumour nodule perpend
e Δ ab = ab before ECT – ab after ECT.
f 1 = same site treated, 2 = other site.computer tomography scan (CT) and 18 F-FDG-PET/CT to evaluate
distant metastasis were required.
The procedure required a hospital stay of 24 h and general
sedation.
Intravenous Bleomycin (Bleomicina Nippon K ﬂ) was injected in an
i.v. bolus (30 s) at a dose of 15000 UI/m2. Electrical pulses started eight
minutes after bolus and treatment was completed 28 min after the end
of infusion [11]. ECT electroporationwas performed using a Cliniporator
device with type III electrodes placed into the lesion (Igea S.p.A. Carpi
Italy). Pulse delivery frequency was 5 kHz at a duration of 100 μs. Elec-
trodes were gently inserted into the skin of the area affected at a depth
of one centimeter; the procedure was repeated progressively covering
all of the area to be treated.
Patients were seen again four weeks after the procedure and then
every four months. During follow-up treatment efﬁcacy was deter-
mined by careful inspection of genitalia and the pelvic region and
all new suspected lesions were mapped and a histological sample
was taken. ECT response criteria was deﬁned according to the WHO
Handbook for Reporting Results of Cancer Treatment [12]: complete
response (CR) when the tumour nodule was not palpable; partial re-
sponse (PR) when the tumour size decreased by more than 50% in the
products of the largest perpendicular diameters of the measurable le-
sions; no change (NC) when the lesion had a reduction b50% and an
increase of up to 25%; progressive disease (PD) when the tumour
size had increased by more than 25%.
To evaluate an improvement in QoL following ECT treatment we
administered visual analogue score (VAS) for pain and vulvar cancer
subscale (VCS) part of functional assessment of vulvar cancer therapy
(FACT-V) for QoL [13], before and four weeks after the procedure.
Willingness to undergo further ECT treatment, if necessary, was
asked to patients.
Statistical analysis
All continuous data are expressed in terms of mean and standard
deviation of the mean and range. Unpaired T test was performed to
investigate response to VCS before and after ECT. p b 0.05 was consid-
ered signiﬁcant. Statistical analysis was carried out by means of the
Statistical Package for the Social Sciences (SPSS) software version
9.0 (SPSS Inc., Chicago, USA).
Results
Between 2009 and 2012, ninewomenwere eligible for the study ac-
cording to the inclusion criteria and were enrolled in the study. Patient
age was 84 ± 3.9 years (mean ± SD) at time of enrolment.
Diagnosis stage of primary tumours, according to the FIGO system,
was: one patient at stage IA, (11%), one patient at stage IB (11%), threeonse Δab After ECT (cm2)e (%) Time R after ECT (days) Location f
−0.8 (57) – –
0 (100) 230 1
0 (100) – –
8.9 (89) – –
0 (100) – –
0 (100) 124 1
2.3 (11) – –
0 (100) – –
on, 5 = emivulva, 6 = inguinal region, l = left, r = right.
icular to a.
Table 2
Descriptive statistics for the vulvar cancer speciﬁc subscale items.
VCS questions Pre-treatment Post-treatment p b 0.05
(mean + SD) (mean + SD)
I am bothered by discharge or bleeding
from my vulva
2.2 + 1.2 3.0 + 1.1 0.04
I am bothered by odor coming from
my vulva
1.5 + 0.8 2.2 + 1.2 0.02
I am afraid to have sex – – –
I am bothered by swelling/ﬂuid in
my legs
3.7 + 0.5 3.8 + 0.4 ns
My vagina feels too narrow or short 2.2 + 0.8 2.5 + 0.5 ns
I am bothered by discomfort in
my groin or legs
3.5 + 0.8 3.7 + 0.5 ns
I am afraid the treatment may
harm my body
2.0 + 0.6 2.7 + 1.0 0.03
I am interested in sex – – –
I like the appearance of my body 1.8 + 0.4 2–0 + 0.1 ns
I am bothered by constipation 2.8 + 1.2 3.0 + 1.1 ns
I have a good appetite 3.2 + 0.8 3.3 + 0.5 ns
I have trouble controlling my urine 1.7 + 0.5 2.0 + 0.9 ns
I am bothered by itching/burning
in my vulva area
1.0 + 0.1 1.3 + 0.5 ns
I have discomfort when I urinate 0.8 + 0.8 1.3 + 0.8 0.04
I am bothered by pain or numbness
in my vulva area
1.2 + 0.4 1.3 + 0.5 ns
I have trouble bending 2.5 + 1.0 2.8 + 0.8 ns
I have discomfort when I am sitting 1.8 + 1.2 2.0 + 1.1 ns
I am bothered by wearing compression
stockings
3.3 + 0.5 3.5 + 0.5 ns
I am able to eat the foods that I like 3.2 + 0.8 3.3 + 0.5 ns
Higher score represent better
quality of life.
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stage IIIB (11%). Eight patients were previously submitted to surgery
and/or radio-chemotherapy and themean time to relapse after last treat-
mentwas 52 ± 49 months (mean ± SD). One patientwas submitted to
ECT without any previous treatment because of age (89 years) and re-
cent gluteal abscess following hip replacement surgery. One patient
was excluded from the study as they were lost during follow-up. Map-
ping of the lesions showed that disease was present in the vulva in
seven of eight patients (87.5%) and in the upper thigh region in one pa-
tient (12.5%).Multiple lesionswere present in two patients (25%). Lesion
characteristics are shown in Table 1.
All patients received treatment under general anaesthesia as de-
scribed in the protocol, with no adverse events observed. Procedure
time was 20 ± 4 min (range 15–28 min). During the procedure thereFig. 1. Pre and post treatment vulvar recurrence. The pictures showed tumour recurrence in
the residual skin was pale and soft and regular.wasminimal blood loss from the application site resulting in an oedema
which disappeared after 24–72 h.
Postoperatively patients did not experience local pain, fever or
nausea; no antibiotic or anti-thrombotic prophylaxis was performed;
patients received oral ﬂuids and a solid diet 3 h after anaesthesia.
Postoperative hospital stay was 24 h for all patients.
We evaluated the response to the therapy after one month and we
observed: CR in ﬁve patients (62.5%), PR in one patient (12.5%), NC in
one patient (12.5%), and PD in one patient (12.5%). In patients with
CR the nodule disappeared and the residual skin was pale and soft
and regular.
After a follow-up of 9.1 ± 3.5 months (mean ± SD) four patients
(50%) were alive. Two patients with CR relapsed after four and seven
months and were candidates for further treatment with ECT. One pa-
tient with PD for age and poor performance status was not submitted
to other treatments and was supported by palliative cure. One patient
was free from disease at the time of follow-up.
All patients responded to VAS and VCS questionnaires pre-treatment,
one month after and six months after the procedure. Evaluation of VAS
and VCS performed one month after treatment showed a signiﬁcant re-
duction in pain (p b 0.03) and a signiﬁcant reduction in bleeding,
odour and urinary discomfort (Table 2). The total VCS score showed a
signiﬁcantly better QoL after treatment (p b 0.001). All patients were
sexually inactive and did not respond to sexual questions. All patients
conﬁrmed that the procedure could be repeated.
Discussion
Our preliminary study showed that ECT can be performed in
loco-regional vulvar cancer recurrence as palliative therapy as the
treatment relieves symptoms and improves patient QoL (Fig. 1).
Although ETC is routinely used with palliative intent in treatment of
cutaneous and subcutaneous tumours of different histological types no
data is available on vulvar squamous cellular cancer. In a recent system-
atic review and meta-analysis Marty et al. [10] evaluated 548 patients
affected bymelanoma, cutaneous sarcoma, Kaposi's sarcoma and breast
cancer relapses treated with bleomycin or cisplatin and ECT. The data
showed CR in 59.4% of cases and PR in 24.7% of cases. Treatmentwas in-
effective in only 15.9% of cases. In the ESOPE study of 62 patients with
skin neoplasia Marty et al. [10] observed a local tumour control rate of
88% with bleomycin given intravenously, 73% with bleomycin given
intra-tumourally and 75% with cisplatin given intra-tumourally. These
data are comparable to the present study where local control of
tumour was achieved in 75% of the patients and CR in 62.5%. Theleft and right minor labia before treatment. After one month the lesion disappeared and
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who demonstrated PD could probably have been treated effectively
with an intra-tumoural drug injection due to ﬁbrosis and the low perfu-
sion of pre-irradiated tissues.
Marty et al. [10] reported higher efﬁcacy of ECTwith intravenous in-
jection of bleomycin for large tumours compared to intra-tumour injec-
tion which they explained was the result of more uniform distribution
of the drugwithin the tumour.We therefore used i.v. bleomycin instead
of local injection and the treatment was effective in small and large
lesions with a 90% reduction observed in a 10 cm2 relapse.
Current treatments of local vulvar cancer relapses are surgery, exter-
nal radiotherapy, brachy-therapy and their combination. Radiotherapy
achieves local control of the tumour but it is not repeatable and cannot
be offered in previously irradiated patients. Surgery is frequently asso-
ciated with delayed healing, lymphedema, local infections and poor
cosmetic results with a decrease in the QoL [14]. ECT was safe with
good cosmetic results obtained in patients who had previously been
treated with surgery and radiotherapy.
In our study the procedure was performed in patients with a short
life-expectancy and the impact on survival was not the main endpoint;
nevertheless patients experienced an improvement in local pain,
discharge, odour and burning with signiﬁcant improvement in QoL.
Our study showed that ECT was very acceptable even in elderly
patients. In fact our group had an average age of 84 years (range
80–90 years) and all patients tolerated the treatment well. This was
conﬁrmed by the willingness to repeat the procedure in all patients.
An advantage of the ECT procedure is also that it is easy and quick
to perform with an average treatment time of 25 min together with a
short hospital stay.
Local or general anaesthesia for ECT has been proposed to relieve
the pain associated with drug injection and electric pulse application.
In our experience general anaesthesia was necessary because of the
sensibility of the vulvar area and to avoid the discomfort of muscle
contraction at the time of pulse delivery.
A limit of our study was the small series of patients treated and the
short follow-up period, a larger scale study is needed to conﬁrmour data.
ECT for local vulvar cancer relapses is to be proposed in a selective
group of heavily pre-treated patients. Local control of the disease isfrequently obtained during the early follow-up period. The procedure
is safe, quick, easily performed and well tolerated.
Longer follow-up is necessary to conﬁrm long term efﬁcacy.
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